Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
株式のランク #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
株価
$62.26
最終同期: 2026-09-22
時価総額
$127.18B
変化(1日)
-0.78%
変化(1年)
38.63%
US
取引 Bristol-Myers Squibb Company (BMY)

カテゴリー

Bristol-Myers Squibb Company(BMY)のP/E比率
September 2026 時点のP/E比率 TTM 14.12
Bristol-Myers Squibb Company の最新の財務報告および株価によると、現在の P/E (TTM) は 14.12 です。2024 年末時点での P/E は -12.81 でした。
Bristol-Myers Squibb Company の P/E 比率の履歴(2000 〜 2026)
各年末のP/E比率
P/E比率 変化
2026 (TTM) 14.12 -9.55%
2025 15.61 -221.83%
2024 -12.81 -196.85%
2023 13.23 -45.39%
2022 24.22 22.34%
2021 19.80 -227.16%
2020 -15.57 -148.93%
2019 31.82 84.46%
2018 17.25 -82.77%
2017 100.10 356.89%
2016 21.91 -70.10%
2015 73.27 50.12%
2014 48.81 43.17%
2013 34.09 22.78%
2012 27.77 71.92%
2011 16.15 10.46%
2010 14.62 211.33%
2009 4.70 -46.38%
2008 8.76 -63.70%
2007 24.13 -25.86%
2006 32.55 117.67%
2005 14.95 -28.23%
2004 20.84 16.81%
2003 17.84 -17.56%
2002 21.64 5.71%
2001 20.47 -30.30%
2000 29.36 0.00%
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差
38.12 169.96%
US
30.79 118.07%
US
73.73 422.20%
US
22.25 57.58%
CH
114.95 714.17%
US
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。